AGMBAgomAb Therapeutics N.V. American Depositary Shares
The schedule
- Mon25Jan
Scheduled Q2 2026 financial results evaluating our assumed $9.50 entry level alongside critical enrollment updates for the ongoing Phase 2 fibrosis trial.
- Mon26Apr
- Mon26Jul
- Mon25Oct
Past
- Wed30Sep
Actual outcome: Bear · $8.72 at outcome
AGMB reported earnings below expectations with lower-than-anticipated revenue guidance, triggering a sharp sell-off. The move reflects investor disappointment in the company's performance and outlook, particularly given the short-term focus of the ultra-short duration bucket. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -21.3% from 2026-09-30 to 2026-10-01 (~3.4σ vs typical 1d vol). Target evaluation date 2026-10-05 (not yet reached as of 2026-10-01). Confidence 95%.
AGMB reported earnings below expectations with lower-than-anticipated revenue guidance, triggering a sharp sell-off. The move reflects investor disappointment in the company's performance and outlook, particularly given the short-term focus of the ultra-short duration bucket. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -21.3% from 2026-09-30 to 2026-10-01 (~3.4σ vs typical 1d vol). Target evaluation date 2026-10-05 (not yet reached as of 2026-10-01). Confidence 95%.
- Mon27Jul
Actual outcome: Bull · $13.16 at outcome
AGMB reported Q1 2025 earnings with EPS exactly matching consensus estimates at -$0.36. The market reacted positively to these in-line results, driving the stock to $12.51 and exceeding the bull target, as the lack of negative surprises reassured investors.
- Mon27Jul
Actual outcome: Bull · $13.16 at outcome
The stock rallied 5.2% despite an EPS miss, as the company met earnings estimates and provided positive guidance on cash runway and cost management. Key clinical milestones were achieved, reinforcing investor confidence in near-term progress and long-term value.
Q1 2026 earnings announcement continuing from the $11.98 spot price, focusing heavily on cash runway, operating expenses, and near-term clinical milestones.